1. Chinese
  2. English
Language entrance:
Hot News:
  1. 1American Regent recalls Phenyle
  2. 2Researchers Tap Yeasts as Sourc
  3. 3GE Healthcare, Rapidscan Pharma
  4. 4Cognizant and Eagle Genomics An
  5. 5Scientists Discover Cancer-Caus
  6. 6Some Effective Natural Deconges
Contact US

    Shanghai Xianjie Chemtech Co.,Ltd.
        Tel:   8621- 5793·2466 
        Fax:   8621- 6192·7З11
        Web:  www.xjchem.net
        Email:  Sales#xjchem.net

Industry News

GE Healthcare, Rapidscan Pharma launch Rapiscan in UK

Promulgator: :chem   Send date: :2011-06-14 Visitor: :

GE Healthcare, Rapidscan Pharma launch Rapiscan in UK


     GE Healthcare and Rapidscan Pharma Solutions have launched Rapiscan (regadenoson), a selective A2A adenosine receptor agonist approved as a pharmacological stress agent for myocardial perfusion scintigraphy in adult patients unable to undergo adequate exercise stress in the diagnosis of coronary artery disease, in the UK.

     Rapidscan Pharma claims Rapiscan is a non-weight based, infusion pump-free pharmacological stress agent available in the UK.

    Unlike older agents, Rapiscan requires no dose adjustment for varying body weight and is administered as a 10 second injection, which cuts the need for an infusion pump, extension line and infusion line set-up.

     Regadenoson was discovered and developed by CV Therapeutics and was approved by the US Food and Drug Administration in April 2008, where it is sold by Astellas Pharma US.

   Gilead Sciences acquired CV Therapeutics in 2009.

      EU Commission Licence was granted by the European Medicine Agency in September 2010.

     In the UK and Germany, Rapiscan (regadensoson) is distributed by GE Healthcare.


Copyright 2004-2009 上海献捷化工科技有限公司 版权所有 友情链接:分散剂 | sitemap